I think you both may have a point (and being overtly pointed with your points). Yes, prurisol trial would add to IPIX's knowledge of prurisol's value. That is very meaningful for license negotiations. But it would be 'present' value, based on present knowledge. RG seems to be speaking about how one can or cannot account for possible other indication.
There is a way. It's called a clause in licensing agreement. Made public usually like this: "... and high single digit royalty for any additional indication ..."
News 
Market Data 
Discover 
